AU2007252506B2 — Antitumor agent for thyroid cancer
Assigned to Eisai R&D Management Co Ltd · Expires 2012-03-29 · 14y expired
What this patent protects
It is intended to provide a pharmaceutical composition exhibiting an effect more effectively on at least one disease selected from the group consisting of multiple endocrine neoplasia type IIA, multiple endocrine neoplasia type IIB, familial medullary thyroid carcinoma, thyroid c…
USPTO Abstract
It is intended to provide a pharmaceutical composition exhibiting an effect more effectively on at least one disease selected from the group consisting of multiple endocrine neoplasia type IIA, multiple endocrine neoplasia type IIB, familial medullary thyroid carcinoma, thyroid cancer, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung's disease, pheochromocytoma, parathyroid hyperplasia and gastrointestinal mucosal neuroma; and a therapeutic method for the same. 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-qunolinecarboxamide and an analog thereof can exhibit an effect more effectively on at least one disease selected from the group consisting of multiple endocrine neoplasia type IIA, multiple endocrine neoplasia type IIB, familial medullary thyroid carcinoma, thyroid cancer, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung's disease, pheochromocytoma, parathyroid hyperplasia and gastrointestinal mucosal neuroma.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.